Clinical Trials
Science
News
About
Connect
- Fundraisers
- Contact Us

Press enter to begin your search

home_os2966dark-fixed

By Onco_staffFebruary 22, 2022

No Comments
0
0
0

Related

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Company Info

Stamford, CT, 06903, USA

info@oncosynergy.com

SSL CERTIFICATE

Latest News

FDA Grants Third Orphan Drug Designation for OS2966 May 3, 2024
OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma April 16, 2021
OncoSynergy Launches Phase I Trial for Patients With Recurrent Glioblastoma November 17, 2020

© 2025 OncoSynergy. All Rights Reserved by OncoSynergy, Inc

Clinical Trials
Science
News
About
Connect
- Fundraisers
- Contact Us